Yesterday I looked at the biotech sector’s outperformance of the headline-grabbing tech and small-cap sectors. Even better, I gave you a way to play it plus a way to juice what should be tidy profits.
But nonetheless, biotech stocks just aren’t getting the same love as the highly touted “FANG” stocks and the like.
But that’s okay with me – more money for the rest of us.
In fact, my “Best in Breed” (BIB) model excels at uncovering underappreciated outperformers. First, it looks for the strongest sectors. Then, it uncovers the highest fliers in those sectors – the cream of the crop.
Today, as promised, I have two biotech names that have not only outperformed this year, but should continue to outpace the large-cap tech media darlings as well as the on-fire small-cap sector.
Though both have outperformed in 2018, each one is subject to analyst skepticism that is not consistent with their technical strength. That’s why I look for their rallies to continue throughout at least the next few months.
Without further ado, let’s take a look at these beasts.
These Have Given a Slew of Double-Digit Returns
First up is Immunomedics Inc. (Nasdaq: IMMU), a stock that just returned a tidy 86% profit for my Seismic Profits Alert subscribers. Immunomedics is a leader in the development of antibody drug conjugates (ADC) to treat aggressive cancers.
After releasing encouraging data for its metastatic breast cancer drug, the company has now submitted a license application to become the first ADC approved to treat an aggressive form of the disease.
t’s clear from Immunomedics’ chart that the Street loves the stock, as the shares have exploded more than 80% in just two months, to hit an 18-year high. IMMU shares are up 57% so far in 2018.
Still, it’s clear not everyone is so keen on it – though I can’t say why.
While positive test results have given the shares a major price boost, it’s the high short interest in IMMU shares that should sustain the rally. With a high short-interest ratio of 16.8, the stock will undoubtedly benefit from a short-covering rally as the stock gains ground.
Another factor in Immunomedics’ favor is the fact that just three analysts currently cover the stock. But with the recent test successes, more analysts will be opening coverage on the stock.
That means rosy price projections that should spur more buying. In fact, one analyst opened coverage this week with a $53 price target, which is more than double Thursday’s close.